Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

In its latest research note, the bank pointed to broadly stable mobile pricing across the main operators. Telecom Italia (BIT ...

Investing.com -- NextEnergy Solar Fund Limited (LON: NESF) on Thursday reported a net asset value (NAV) of 91.7p per share as of June 30, representing a 3.6% decline from the previous quarter.

Finland’s Kojamo (HE: KOJAMO) reported a modest rise in revenue but weaker profitability in the second quarter of 2025, as ...

Novonesis narrowed its full-year organic sales growth outlook to 6–8% from 5–8% and maintained its EBITDA margin guidance of ...

The preliminary S&P Global (NYSE: SPGI) UK Composite Purchasing Managers’ Index rose to 53.0, its highest level since August 2024 and a significant improvement from July’s final reading of 51.5. The ...

Investing.com -- The European Union-United States trade deal does not currently include the wine and spirits sector, European Union Trade Commissioner Maros Sefcovic said on Thursday. Sefcovic noted ...

Investing.com -- Barclays (LON: BARC) has raised its forecast for euro area inflation in 2025, now expecting headline consumer prices to average 2.1% compared with the 2% projection it published in ...

Investing.com -- China Petroleum (OTC: SNPTY) & Chemical Corp., known as Sinopec (OTC: SHIIY ), reported a 40% decline in net profit for the first half of 2025, as lower oil prices weighed on the ...

Bullard stated that interest rates "are high right now" and suggested the Fed could cut rates by 100 basis points into 2026. He added that the central bank could implement further cuts in 2026 ...

The joint statement noted that the U.S. agreed to apply only pre-existing Most Favored Nation (MFN) tariffs of below 15% from September 1 on EU aircraft and parts, generic pharmaceuticals and ...

Investing.com -- Morgan Stanley (NYSE: MS) has initiated coverage of Trevi Therapeutics (NASDAQ: TRVI) with an “overweight” rating and a price target of $18. The brokerage flags Trevi’s development of ...